Get A Drip Mounjaro Cost: UK Pricing and Service Guide

Written by

Bolt Pharmacy

Published

25/11/2025

Last Updated

5/8/2026

Weight loss treatments

GLP-1 / GIP

Mounjaro

Prices from

£149.00

Learn more about Mounjaro

GLP-1

Wegovy

Prices from

£99.00

Learn more about Wegovy

Understanding the cost of Mounjaro through private providers such as Get A Drip is essential for those considering this treatment for type 2 diabetes or weight management. Mounjaro (tirzepatide) is a once-weekly injectable medication that works as a dual GIP and GLP-1 receptor agonist, licensed in the UK for specific indications. Private treatment typically costs between £123–£269 (price-comparison listing, checked 4 August 2026) per month, depending on dose strength and service package. This article examines Get A Drip’s Mounjaro pricing structure, what’s included in their service, and how private access compares with NHS pathways, helping you make an informed decision about your treatment options.

Summary: Get A Drip Mounjaro costs typically range from £123–£269 (price-comparison listing, checked 4 August 2026) per month for private prescriptions.

Mounjaro (tirzepatide) is a dual GIP and GLP-1 receptor agonist licensed in the UK for type 2 diabetes and chronic weight management in adults meeting specific BMI criteria.
The medication is administered as a once-weekly subcutaneous injection, starting at 2.5 mg and titrating up to a maximum of 15 mg based on individual response.
Common adverse effects include nausea, vomiting, diarrhoea, and abdominal discomfort, which are generally mild to moderate and diminish over time.
Private services typically include initial medical consultation, prescription supply, injection training, dose titration guidance, ongoing clinical monitoring, and lifestyle support.
NHS access follows NICE guidance with specific eligibility criteria and is delivered through specialist weight management services, whilst private access offers faster availability at out-of-pocket cost.
Women using oral contraceptives require additional barrier contraception for 4 weeks after starting treatment and after each dose increase due to potential medication interactions.

What Is Mounjaro and How Does It Work?

Mounjaro (tirzepatide) is a prescription medicine licensed in the UK for the treatment of type 2 diabetes mellitus and for chronic weight management in adults with a BMI ≥30 kg/m², or ≥27 kg/m² with at least one weight-related comorbidity, as an adjunct to diet and physical activity. It is administered as a once-weekly subcutaneous injection and belongs to a novel class of medicines known as dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonists.^[2]^[3]

The mechanism of action of Mounjaro involves mimicking two naturally occurring incretin hormones. By activating both GIP and GLP-1 receptors, tirzepatide enhances insulin secretion in a glucose-dependent manner, suppresses glucagon release, slows gastric emptying, and reduces appetite. This dual action results in improved glycaemic control in people with type 2 diabetes and significant weight loss in those using it for obesity management.

Mounjaro is available in several dose strengths, starting at 2.5 mg for 4 weeks, then increasing in 2.5 mg steps (to 5 mg, 7.5 mg, 10 mg, 12.5 mg, and up to 15 mg) based on individual response and tolerability. The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Mounjaro for use in the UK, and the National Institute for Health and Care Excellence (NICE) has issued guidance on its use within the NHS for specific indications.

Common adverse effects include nausea, vomiting, diarrhoea, constipation, and abdominal discomfort, which are generally mild to moderate and tend to diminish over time.^[2]^[3] Important safety considerations include: avoiding use in pregnancy and breastfeeding; potential interaction with oral contraceptives (additional barrier contraception is advised for 4 weeks after initiation and after each dose increase); risk of hypoglycaemia when combined with insulin or sulfonylureas; and monitoring for diabetic retinopathy in those with type 2 diabetes. Mounjaro is not indicated for type 1 diabetes or diabetic ketoacidosis.

Feature	NHS Access	Private Access (e.g. Get A Drip)
Monthly medication cost	Standard prescription charge (£9.90 per item in England)	Approximately £150–£300 per month, depending on dose
Eligibility criteria	BMI ≥35 kg/m² (or ≥32.5 kg/m² in certain ethnic groups) plus ≥1 comorbidity; specific HbA1c criteria for type 2 diabetes (NICE TA924, TA1058)	Medical suitability assessment required; BMI ≥27 kg/m² with comorbidity or ≥30 kg/m²
Speed of access	Dependent on specialist weight management service capacity; may involve waiting lists	Initial consultation typically within days; treatment can begin promptly
Included support	Clinical monitoring via specialist services; lifestyle support varies by service	Injection training, dose titration guidance, dietary and lifestyle coaching, ongoing monitoring
Prescription and supply	Issued via NHS specialist or GP under NICE-approved pathway	Issued by UK-registered clinician; CQC/GPhC-compliant dispensing, often with home delivery
Reporting adverse effects	MHRA Yellow Card scheme; contact GP or NHS 111	Contact prescribing clinician; MHRA Yellow Card scheme; NHS 111 or 999 in emergency

Get A Drip Mounjaro Cost and Pricing Structure

Get A Drip is a private healthcare provider offering a range of wellness and medical services, including weight management programmes that may incorporate medications such as Mounjaro. The cost of Mounjaro through private providers typically includes not only the medication itself but also associated clinical consultations, monitoring, and support services.

As of early 2024, private Mounjaro prescriptions in the UK generally range from £150 to £300 per month, depending on the dose strength and the provider’s service package. However, prices may vary and are subject to change, particularly given ongoing supply constraints affecting GLP-1 receptor agonist medications in the UK. Patients should confirm current costs directly with Get A Drip or their dispensing pharmacy.

Private treatment costs typically include:

Monthly medication cost: The price of the Mounjaro pen injections, which varies according to the prescribed dose.
Follow-up consultations: Regular monitoring appointments to assess progress, manage side effects, and adjust dosing as needed.

It is important to note that while Mounjaro has received NICE approval (TA1058) for weight management in adults with a BMI ≥35 kg/m² (or ≥32.5 kg/m² in certain ethnic groups) and at least one weight-related comorbidity, NHS access is through specialist weight management services and may be limited by service capacity. For type 2 diabetes, NICE guidance (TA924) recommends tirzepatide in specific circumstances within the treatment pathway. NHS prescriptions are subject to standard prescription charges (currently £9.90 per item in England, though this may change; see the NHS Business Services Authority website for current charges).

What’s Included in the Get A Drip Mounjaro Service

When accessing Mounjaro through Get A Drip, patients typically receive a comprehensive, medically supervised weight management service rather than simply a prescription. This holistic approach is designed to maximise safety, efficacy, and long-term success.

Key components of the Get A Drip Mounjaro service include:

Initial medical consultation: A thorough assessment by a qualified UK-registered healthcare professional, including review of medical history, current medications, weight and metabolic health status, and suitability for tirzepatide therapy. This may be conducted in person or via telemedicine.
Prescription and supply: Once deemed appropriate, a prescription for Mounjaro is issued, and the medication is supplied through CQC/GPhC-compliant dispensing, often with home delivery options.
Injection training: Instruction on proper injection technique, site rotation, storage requirements, and safe sharps disposal.
Dose titration guidance: Clear instructions on how to start at a lower dose and gradually increase to the target maintenance dose, minimising gastrointestinal side effects.
Ongoing clinical monitoring: Regular follow-up appointments to monitor weight loss progress, assess tolerability, review blood glucose levels if relevant, and adjust treatment as necessary. Treatment continuation is typically reviewed at 6 months, aligned with NICE guidance on response thresholds.
Lifestyle and dietary support: Nutritional advice, exercise guidance, and behavioural coaching to complement pharmacotherapy.
Safety monitoring: Vigilance for potential adverse effects and contraindications. Patients are advised to seek urgent medical attention for signs of pancreatitis (severe abdominal pain radiating to the back), gallbladder disease, persistent vomiting, severe dehydration, significant hypoglycaemia, or allergic reactions.

Important safety considerations include that Mounjaro is not indicated for those under 18, during pregnancy or breastfeeding, or for people with type 1 diabetes. Women using oral contraceptives should use additional barrier contraception for 4 weeks after starting treatment and after each dose increase.^[13]^[14]

NHS vs Private Mounjaro: Comparing Your Options

Understanding the differences between accessing Mounjaro via the NHS versus private providers like Get A Drip is essential for making an informed decision about your treatment pathway.

NHS Access:

Mounjaro is licensed for use in the UK, but NHS availability follows specific pathways. For type 2 diabetes, NICE guidance (TA924) recommends tirzepatide within the treatment pathway outlined in NG28, with specific continuation criteria based on HbA1c response. For weight management, NICE has issued guidance (TA1058) recommending tirzepatide for chronic weight management in adults with a BMI ≥35 kg/m² (or ≥32.5 kg/m² in certain ethnic groups) and at least one weight-related comorbidity, delivered through specialist weight management services. While NICE technology appraisals have a funding mandate within 3 months in England, practical availability may depend on specialist service capacity and ongoing supply constraints.

Private Access (e.g, Get A Drip):

Private providers offer faster access to Mounjaro without the need for NHS referral pathways. Patients can typically arrange an initial consultation within days and begin treatment promptly if deemed suitable. The cost is entirely out-of-pocket, ranging from £150 to £300 per month. Private services often provide more personalised care and flexible appointment scheduling.

Key considerations when comparing options:

Eligibility: NHS access requires meeting specific clinical criteria; private access still requires medical suitability assessment.
Cost: NHS prescriptions are subject to standard prescription charges; private treatment incurs significant monthly costs.
Speed: Private access is typically faster; NHS access depends on local service availability.
Support: Both pathways should include appropriate monitoring and lifestyle support.

Patients should discuss their individual circumstances with their GP or a private healthcare provider to determine the most appropriate pathway. If you experience any adverse effects or have concerns about Mounjaro, contact your prescribing clinician or GP promptly. For urgent advice, contact NHS 111, or call 999 in an emergency. Suspected side effects can be reported to the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk or via the Yellow Card app.

Scientific References

Frequently Asked Questions

How much does Mounjaro cost through Get A Drip?

Mounjaro through Get A Drip typically costs between £123–£269 (price-comparison listing, checked 4 August 2026) per month, depending on the prescribed dose strength and service package. An initial consultation fee is usually required, and prices may vary based on current supply and individual treatment requirements.

What is included in the Get A Drip Mounjaro service?

The service includes an initial medical consultation with a UK-registered healthcare professional, prescription and medication supply, injection training, dose titration guidance, ongoing clinical monitoring with regular follow-up appointments, lifestyle and dietary support, and safety monitoring for potential adverse effects.

Can I get Mounjaro on the NHS instead of privately?

Yes, Mounjaro is available on the NHS following NICE guidance for type 2 diabetes (TA924) and weight management (TA1058) in adults meeting specific BMI and comorbidity criteria. NHS access is through specialist weight management services and may depend on local service capacity, whilst private access through providers like Get A Drip offers faster availability at out-of-pocket cost.